Aneel Bole, MD
Interventional Cardiology · Erie, PANPI 1275822264
Payments from drug & device makers
Across 302 payments — averaging $62.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$5K
- Edwards Lifesciences$3K
- Medtronic$2K
- Baylis Medical Company Inc$1K
- Medical Device Business Services, Inc.$1K
- Boston Scientific$1K
- plus $4K from 23 others
What the payments were for
- Travel & lodging$6,77436%
- Food & beverage$11,97964%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 100 | $4,742 |
| Edwards Lifesciences | 22 | $3,345 |
| Medtronic(2 entities) | 23 | $2,338 |
| Baylis Medical Company Inc | 6 | $1,375 |
| Medical Device Business Services, Inc. | 10 | $1,331 |
| Boston Scientific | 26 | $1,329 |
| W. L. Gore & Associates, Inc. | 9 | $763 |
| Abiomed | 13 | $581 |
| Stryker | 13 | $501 |
| Amgen | 11 | $387 |
| Abbott | 8 | $315 |
| E.r. Squibb & Sons, L.L.C. | 11 | $202 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $198 |
| Boehringer Ingelheim | 3 | $184 |
| Shockwave Medical, Inc | 3 | $174 |
| Novartis | 10 | $166 |
| AstraZeneca | 3 | $156 |
| Cardiovascular Systems Inc. | 4 | $149 |
| Esperion Therapeutics, Inc. | 8 | $146 |
| Penumbra, Inc. | 1 | $120 |
| Pfizer | 4 | $61 |
| Merck | 3 | $39 |
| Heartflow, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $35 |
| Johnson & Johnson | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Terumo Medical Corporation | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,964
- FLOWTRIEVER CATHETER, S$1,312
- CT THROMBECTOMY SYSTEM KIT$1,312
- VersaCross Access Solution$1,245
- Carto 3 System$1,244
- CoreValve Evolut$1,207
- WATCHMAN FLX$804
- GORE CARDIOFORM Septal Occluder$528
- COREVALVE EVOLUT R$278
- Impella$138
- RESOLUTE ONYX$138
- AMPLATZER AMULET$128
- BRILINTA$125
- Repatha$125
- JARDIANCE$123
- Penumbra System$120
- FlowTriever$118
- LifeVest$108
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$103
How this compares
$18,753 in reported general payments places this provider in the 60th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 233 | $280,078 |
| EntrestoSacubitril/Valsartan | 176 | $231,896 |
| Repatha SureclickEvolocumab | 195 | $159,158 |
| EliquisApixaban | 85 | $102,624 |
| FarxigaDapagliflozin Propanediol | 75 | $89,295 |
| Repatha PushtronexEvolocumab | 59 | $58,789 |
| BrilintaTicagrelor | 57 | $49,377 |
| Praluent PenAlirocumab | 43 | $40,028 |
| Ranolazine ErRanolazine | 241 | $20,025 |
| JardianceEmpagliflozin | 11 | $15,563 |
| Repatha SyringeEvolocumab | 21 | $15,388 |
| CorlanorIvabradine Hcl | 11 | $6,311 |
| Metoprolol Succinate | 577 | $6,292 |
| Atorvastatin Calcium | 360 | $4,845 |
| Rosuvastatin Calcium | 222 | $2,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $17 | $280,078233 claims |
| NovartisEntresto | $166 | $231,896176 claims |
| AstraZenecaFarxiga, Brilinta | $156 | $138,672132 claims |
| PfizerEliquis | $61 | $102,62485 claims |
| Boehringer IngelheimJardiance | $184 | $15,56311 claims |
| AmgenCorlanor | $387 | $6,31111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Erie
- Matthew BeckerErie$1.3M
- Orestis PappasErie$551K
- Gurjaipal KangErie$463K
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- David LasordaPittsburgh$1.1M
- Nainesh PatelAllentown$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.